UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone646-768-9780
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$1.13 million
Profitability
Miscellaneous
Employees70
Next Earnings Date11/11/2019 (Estimated)
OptionableOptionable
Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions
What is Urogen Pharma's stock symbol?
Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."
How were Urogen Pharma's earnings last quarter?
Urogen Pharma Ltd (NASDAQ:URGN) announced its quarterly earnings results on Friday, August, 9th. The company reported ($1.08) EPS for the quarter, beating the Zacks' consensus estimate of ($1.20) by $0.12. The business had revenue of $0.02 million for the quarter. View Urogen Pharma's Earnings History.
When is Urogen Pharma's next earnings date?
What price target have analysts set for URGN?
8 brokers have issued twelve-month price objectives for Urogen Pharma's shares. Their forecasts range from $41.00 to $77.00. On average, they expect Urogen Pharma's share price to reach $61.8571 in the next twelve months. This suggests a possible upside of 70.3% from the stock's current price. View Analyst Price Targets for Urogen Pharma.
What is the consensus analysts' recommendation for Urogen Pharma?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 2 hold ratings and 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Urogen Pharma.
What are Wall Street analysts saying about Urogen Pharma stock?
Here are some recent quotes from research analysts about Urogen Pharma stock:
- 1. According to Zacks Investment Research, "UroGen Pharma Ltd. is a clinical stage biopharmaceutical company. It focused on developing urological pathologies with a focus on uro-oncology. The company's product candidates include MitoGel and VesiGel which are in clinical trial stage. Its platform technologies include: RTGel and Immunotherapy. UroGen Pharma Ltd. is based in Ra'anana, Israel. " (7/30/2019)
- 2. Stifel Nicolaus analysts commented, "We are reiterating our Buy rating on URGN shares post its 4Q18 financial report and business update. We remain bullish on its lead program, MitoGel (UGN-101) which is being developed as a non-surgical treatment option for patients with upper tract urothelial carcinoma (UTUC), a niche, but high unmet need patient population. We continue to await the completion of URGN’s OLYMPUS Phase 3 study for MitoGel in UTUC, which we previously estimated could finish in the August 2019 timeframe in order for ~75% of patients achieving a CR to reach the 6-month time point. While there was not much new in terms of an update on last week’s conference call, we believe the company remains well positioned to execute on its plan to complete its rolling NDA submission in the 2H19 setting up a 1H20 launch along with the ability to leverage its RTGel platform for business development opportunities." (3/5/2019)
Has Urogen Pharma been receiving favorable news coverage?
Press coverage about URGN stock has been trending negative on Tuesday, according to InfoTrie Sentiment. InfoTrie scores the sentiment of press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Urogen Pharma earned a news impact score of -2.9 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the stock's share price in the next few days. View News Stories for Urogen Pharma.
Who are some of Urogen Pharma's key competitors?
Some companies that are related to Urogen Pharma include Akcea Therapeutics (AKCA), Nabriva Therapeutics (NBRV), Ligand Pharmaceuticals (LGND), Deciphera Pharmaceuticals (DCPH), Prestige Consumer Healthcare (PBH), Zogenix (ZGNX), Uniqure (QURE), Apellis Pharmaceuticals (APLS), Insmed (INSM), Tricida (TCDA), Eidos Therapeutics (EIDX), Heron Therapeutics (HRTX), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Madrigal Pharmaceuticals (MDGL).
What other stocks do shareholders of Urogen Pharma own?
Who are Urogen Pharma's key executives?
Urogen Pharma's management team includes the folowing people:
- Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)
- Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)
- Mr. Stephen Mullennix, Chief Operating Officer
- Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
- Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director
When did Urogen Pharma IPO?
(URGN) raised $46 million in an IPO on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.
Who are Urogen Pharma's major shareholders?
Urogen Pharma's stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (9.73%), Highline Capital Management L.P. (7.37%), Wildcat Capital Management LLC (6.13%), Clal Insurance Enterprises Holdings Ltd (4.03%), Delek Group Ltd. (2.97%) and Citadel Advisors LLC (0.74%). Company insiders that own Urogen Pharma stock include Mark Schoenberg, Peter P Pfreundschuh, Proquest Investments Iv, LP and Stephen Mullennix. View Institutional Ownership Trends for Urogen Pharma.
Which major investors are selling Urogen Pharma stock?
URGN stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Man Group plc, Citadel Advisors LLC, Morgan Stanley, Shikiar Asset Management Inc., Alps Advisors Inc., LLBH Private Wealth Management LLC and Clal Insurance Enterprises Holdings Ltd. Company insiders that have sold Urogen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix. View Insider Buying and Selling for Urogen Pharma.
Which major investors are buying Urogen Pharma stock?
URGN stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Delek Group Ltd., Wildcat Capital Management LLC, Vanguard Group Inc., Bank of New York Mellon Corp, Pathstone Family Office LLC, Charles Schwab Investment Management Inc. and Northern Trust Corp. View Insider Buying and Selling for Urogen Pharma.
How do I buy shares of Urogen Pharma?
Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Urogen Pharma's stock price today?
One share of URGN stock can currently be purchased for approximately $36.33.
How big of a company is Urogen Pharma?
Urogen Pharma has a market capitalization of $499.57 million and generates $1.13 million in revenue each year. The company earns $-75,660,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.View Additional Information About Urogen Pharma.
What is Urogen Pharma's official website?
How can I contact Urogen Pharma?
Urogen Pharma's mailing address is 499 Park Avenue, New York NY, 10014. The company can be reached via phone at 646-768-9780 or via email at [email protected]
MarketBeat Community Rating for Urogen Pharma (NASDAQ URGN)
MarketBeat's community ratings are surveys of what our community members think about Urogen Pharma and other stocks. Vote "Outperform" if you believe URGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe URGN will underperform the S&P 500 over the long term. You may vote once every thirty days.
